– ALYFTREK ™ is approved for patients 6 years and older with at least one responsive mutation, including 31 additional mutations not responsive to other CFTR modulator therapies – – In head-to-head ...

It's been a solid year for many, with all three indexes heading for triple-digit gains, and with the right mix of stocks, we ...

Vertex Pharmaceuticals seems likely to enjoy an end-of-year rebound ... The FDA is scheduled to announce its decision on ...

Recent health news highlights include a landmark ruling by the Inter-American Court of Human Rights concerning abortion ...